Zitanid

Quick links to important sections

Zitanid

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zitanid

Property Description
Active Ingredient Tizanidine Hydrochloride
Form Tablet (Oral dosage form)
Pharmacological Class Centrally acting skeletal muscle relaxant
Common Use Symptomatic treatment of muscle spasticity
Origin Synthetic (Imidazoline derivative)

Zitanid: Defining the Type and Classification

Zitanid is a prescription-only, single-ingredient medication containing the active substance Tizanidine Hydrochloride. It is formally classified as a centrally acting skeletal muscle relaxant and is chemically designated as a synthetic Imidazoline derivative.

The Zitanid formulation is specifically a rapid-release oral tablet, intended for systemic administration throughout the body. This classification highlights that the compound works by influencing the central nervous system, rather than acting directly on muscle tissue.


Composition and General Therapeutic Purpose

The essential composition of Zitanid centers entirely on its active ingredient, Tizanidine Hydrochloride, which is embedded within a solid oral matrix.

This active compound is directly responsible for the drug’s general therapeutic purpose: to provide symptomatic treatment for conditions involving heightened muscle tone and involuntary, painful muscle spasms (spasticity). The medication’s primary goal is to help relax stiff or tight muscles by intervening in the central neural signal pathways, offering relief from the chronic muscle overactivity associated with various central nervous system disorders.


Tizanidine's Action on Central Muscle Control

Zitanid’s specific mechanism is based on its function as an alpha-2 adrenergic agonist, modulating nerve activity primarily within the brain and spinal cord to achieve muscle relaxation.

The Tizanidine molecule acts by selectively stimulating specific alpha-2 receptors on nerve cells, which leads to a controlled reduction in the release of excitatory neurotransmitters that command muscles to contract. This focused, centrally mediated reduction in nerve signaling effectively "turns down" the neural excitability that causes muscle tension.

What side effects are possible with Zitanid?

Possible Side Effects and Safety Information

The safety profile of Zitanid (Tizanidine), a centrally acting muscle relaxant, is defined by adverse reactions primarily related to its effect on the central nervous system and cardiovascular system, as documented in regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency based on clinical study data:

  • Very Common (ge 10%): The most frequently reported effects are dry mouth, somnolence (drowsiness), asthenia (weakness), and dizziness.
  • Common (1% to 10%): Effects include hypotension (low blood pressure), bradycardia (slow heart rate), nausea, and abnormal liver function tests.

Serious Adverse Reactions and Systemic Concerns

Official documents highlight the potential for clinically significant, though less frequent, reactions:

  • Hepatotoxicity: Cases of hepatocellular liver injury have been observed, with elevations in liver enzymes classified as common. Rarely, severe hepatotoxicity has been reported.
  • Cardiovascular Events: The risk of severe hypotension may lead to syncope (fainting), particularly during initial dose escalation.
  • Psychiatric Effects: Tizanidine use has been associated with reports of hallucinations and psychotic-like symptoms.

Population and Time-Related Safety Patterns

Safety notes are explicitly documented for certain contexts and populations:

  • Renal Impairment: Clearance is significantly reduced in patients with severe renal impairment (< 25 mL/min), increasing the potential for adverse reactions.
  • Treatment Initiation: The potential for sedation and hypotension may be more pronounced at the start of treatment and during initial dose increases.
  • Abrupt Cessation: Sudden discontinuation, particularly after chronic high-dose use, may cause withdrawal adverse reactions such as rebound hypertension and tachycardia.

Safety Restrictions

Co-administration with potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) is contraindicated due to the risk of severe hypotension and excessive somnolence from increased drug concentrations.

Overdose and Emergency Response

Overdose and when to seek help

Zitanid overdose is documented in regulatory labeling as resulting in clinical manifestations consistent with its pharmacology as a centrally acting agent. The primary reported signs involve significant Central Nervous System (CNS) depression, presenting as lethargy, somnolence, confusion, and stupor, potentially progressing to coma. Severe cardiovascular instability is also a documented feature, characterized by marked hypotension (low blood pressure) and bradycardia (slow heart rate). Other signs include respiratory depression, hypotonia, and hypothermia.

Life-threatening outcomes such as respiratory failure and fatality have been reported, particularly in cases involving the concomitant ingestion of multiple drugs, including other CNS depressants. Patients with severe renal impairment (creatinine clearance less than 25 mL/min) are noted in labeling as being at a higher risk of toxicity.

When to Seek Immediate Medical Attention

Regulatory authorities mandate that any individual with a suspected overdose seek immediate emergency medical attention. Contacting the regional Poison Control Center is the official, regulator-directed action. The official management described focuses strictly on providing symptomatic and supportive treatment. No specific antidote is known for Tizanidine, and dialysis is documented as not being an efficient method of drug removal. Required procedural interventions include ensuring the adequacy of an airway and continuous monitoring of both cardiovascular and respiratory systems.

Therapeutic Uses of Zitanid

What Zitanid Treats: Main Uses and Benefits

Zitanid (Tizanidine) is an anti-spastic agent applied to provide symptomatic support for chronic neurological disorders marked by severe muscle overactivity. It is commonly used as a skeletal muscle relaxant to help address symptoms related to heightened neurological or muscular activity, such as muscle spasms and stiffness. Its therapeutic goal is solely to ease the symptoms that lead to significant functional strain and patient distress.


Relief of Pathological Muscle Tightness and Spasms

The medication is commonly used to help address symptom clusters related to heightened neurological or muscular activity, specifically pathological muscle hypertonia (severe stiffness) and involuntary muscle spasms (including clonus). It is relevant in conditions characterized by periods of heightened symptoms, such as those associated with Multiple Sclerosis (MS) or Spinal Cord Injury (SCI). Through its role in managing symptoms of increased neurological or muscular activity, Zitanid is relevant for easing symptoms related to physical discomfort and heightened physiological activity, which may interfere with daily functioning, and which contributes to easing the overall symptom load during difficult episodes.

The core indications for which Zitanid is considered relevant include spasticity resulting from neurological damage like multiple sclerosis, spinal cord injury, stroke recovery phases, and traumatic brain injury sequelae.


Support for Functional Mobility in Chronic Conditions

Zitanid is applied across domains where additional symptomatic support is needed, particularly in chronic conditions like post-Stroke recovery or Traumatic Brain Injury (TBI) sequelae where symptoms create noticeable interference with daily functioning. Its use supports the patient in managing symptoms that interfere with functional stability. Through its role in managing symptoms of increased neurological or muscular activity, it contributes to improved comfort during periods of heightened symptoms, and supports general well-being during symptomatic phases, may assist with maintaining functional stability and is relevant for managing symptoms that interfere with routine activities.

“It is commonly used to help address symptom clusters that may become intense or disruptive in conditions where functional stability becomes affected.”

Quick Fact: Symptomatic Support Zitanid is relevant in clinical settings that involve acute or unstable symptom patterns of muscle hypertonia, and it helps address symptom clusters that interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus overview on Tizanidine

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Zitanid?

Zitanid (Tizanidine) eligibility is strictly defined by regulatory documents, outlining populations permitted to use the medication and those who are expressly prohibited.

Absolute Contraindications

Zitanid must not be used by patients with known hypersensitivity to the drug or any of its components, or by patients with severe hepatic impairment (significantly impaired liver function). The medicine is also contraindicated for any patient concurrently taking the potent CYP1A2 inhibitors Fluvoxamine or Ciprofloxacin.

Age-Group and Physiological Restrictions

Use is approved for adults (18 years and older). It is not recommended for children and adolescents as safety and efficacy have not been established in the pediatric population. Elderly patients (65 and older) should use the drug with caution due to reduced clearance.

Zitanid is not recommended for use during pregnancy or by breastfeeding women. Use is also restricted with caution in patients with renal impairment (Creatinine Clearance < 25 mL/min) and in those with moderate hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zitanid (Tizanidine) has officially documented interaction patterns based on its metabolic pathway and central nervous system effects.

Contraindicated and High-Risk Combinations

Co-administration with potent CYP1A2 inhibitors, specifically Fluvoxamine and Ciprofloxacin, is formally contraindicated in regulatory documents. These combinations dramatically increase Tizanidine plasma concentrations, leading to severe adverse reactions. Less potent CYP1A2 inhibitors, such as Oral Contraceptives, Cimetidine, or Acyclovir, should be avoided or used with extreme caution, as they can also elevate Tizanidine serum levels by reducing clearance.

Pharmacodynamic and Exposure Interactions

Zitanid can cause additive sedative effects when combined with alcohol or other CNS depressants (e.g., opioids, benzodiazepines). This combination increases the risk of excessive drowsiness. As an alpha-2 adrenergic agonist, Tizanidine may also potentiate the hypotensive effect of concurrent antihypertensive products. Regarding exposure modification, Rifampicin and smoking are documented to reduce Tizanidine plasma levels. For the tablet formulation, taking it with food, particularly a high-fat meal, increases the maximal plasma concentration (C max), requiring consistent administration (always with food or always without) to maintain stable exposure.

Mechanism of Action

Zitanid is a selective Janus Kinase 3 (JAK-3) inhibitor. The molecule acts intracellularly, binding directly to the ATP-binding pocket of the JAK-3 catalytic domain, thereby blocking its intrinsic tyrosine kinase activity.

This specific molecular interaction prevents the subsequent phosphorylation of STAT (Signal Transducer and Activator of Transcription) proteins. By inhibiting JAK-3 activity, Zitanid prevents the activation of several high-affinity cytokine receptors, specifically those for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.

This action modulates the downstream signaling cascade of cytokines that rely on the JAK-STAT pathway for signal transduction within the cell.

This cascade modification results in the decreased transcription of pro-inflammatory genes within immune cells and reduces the concentration of circulating inflammatory biomarkers.

Dosage and Administration Information

How Zitanid is Used: Official Administration Guidelines

Usage of Zitanid is defined by a structured, individualized regimen focused strictly on oral administration. The medication is supplied as a 2 mg and 4 mg oral tablet and is intended for systemic delivery.

Standard Dosing Protocol

Treatment initiates with a low dose of 2 mg, which is then gradually increased, or titrated, by increments of 2 mg to 4 mg every one to four days until the appropriate amount is determined. This individualized titration is essential, though the dose must never exceed the specified maximum daily limit of 36 mg. The determined total daily amount must be divided and administered up to three times per day, typically at regular intervals of six to eight hours, to align with the drug's short period of activity.

Administration Conditions and Duration

A key instruction is the need for consistent administration relative to meals; the patient must always take the drug with food or always without it. When treatment is discontinued, the process is not immediate but requires a slow, gradual reduction (tapering) of the dose by 2 mg to 4 mg per day. Specific protocols also apply to individuals with renal impairment, who are instructed to use lower starting doses and adjust the dosage cautiously, while use in the pediatric population is not established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zitanid

This overview describes the types of clinical research conducted for Zitanid (Tizanidine) and what the studies monitored, based on authoritative regulatory and peer-reviewed scientific sources. Findings describe group patterns observed in research and reflect the specific conditions under which the studies were conducted.


Evidence for Spasticity Associated with Multiple Sclerosis (MS)

Research primarily involved short-term, randomized controlled trials (RCTs) using double-blind comparisons against a placebo. Studies monitored objective measurements of muscle tone and tracked the frequency and severity of muscle spasms among adult participants with MS. Studies examined how measured muscle tone changed in the observed populations during the short-term study periods.

However, the existing studies provide limited information on functional measures. Data for certain groups remain insufficient, and the evidence related to consistent, objective changes in daily functioning or activity level was inconsistent across trials. Furthermore, the long-term effects are not fully established in large, controlled populations.

Evidence for Spasticity Following Spinal Cord Injury (SCI)

Zitanid was evaluated in the context of spasticity arising from chronic Spinal Cord Injury (SCI) through controlled trials. Studies monitored outcomes related to physiological strain, primarily focusing on objective measurements of muscle tone and the frequency of involuntary muscle spasms (clonus) in adult patients with chronic SCI. A key limitation is that Follow-up durations were limited in many of the core trials, meaning there is limited information for long-term outcomes.

Evidence for Spasticity Following Acquired Brain Injury (Stroke/TBI)

Studies was observed in the context of spasticity following events like stroke or Traumatic Brain Injury (TBI), involving controlled and open-label designs. Research examined changes in muscle tone using standardized scales and also explored outcomes related to physical discomfort, such as the reported pain frequency associated with the muscle tightness. The overall evidence base is smaller and often more heterogeneous. The use of Zitanid in the acute phase immediately following the injury is not well established by research.

Key Studies & References

  1. Public Assessment Report Scientific discussion Tizagelan 2 mg and 4 mg tablets (tizanidine hydrochloride) (EMA/National Agency Equivalent)

Frequently Asked Questions (FAQ)

Common questions about Zitanid (FAQ)

Q: Is Zitanid considered a long-term treatment option?

Official documentation advises that there is limited clinical experience regarding the duration of use in controlled studies. The length of time Zitanid is used is defined on an individualized basis.


Q: Can Zitanid affect blood pressure?

Yes, regulatory documents state that Zitanid is associated with hypotension (low blood pressure) and bradycardia (slow heart rate). It can also enhance the blood pressure-lowering effects of concurrent antihypertensive medications.


Q: Is it possible for Zitanid to stop working after long-term use?

For some patients, physical dependence may develop with regular, long-term use. The official information also notes that sudden cessation can lead to withdrawal effects, such as a sharp increase in blood pressure or heart rate.


Q: What kind of monitoring is officially described as necessary while using Zitanid?

Official guidelines suggest that monitoring of liver enzyme levels is important during the initial phase of treatment, typically occurring at specific intervals during the first six months of use.


Q: Is Zitanid known to cause stomach upset or digestive issues?

Yes, dry mouth is a very common side effect reported in clinical studies. Other digestive issues that have been reported include nausea and vomiting.


Q: Can Zitanid interfere with birth control pills?

Studies indicate that taking Zitanid along with oral contraceptives can reduce the clearance of Zitanid from the body. This interaction may result in higher levels of Zitanid and potentially increase the chance of experiencing adverse effects.


Q: Does Zitanid interact with common supplements like multivitamins?

Regulatory documents do not list specific interactions with standard multivitamins. However, official labeling focuses on known interactions involving certain liver enzymes and central nervous system depressants.


Q: How long does it typically take before a person might notice Zitanid working?

According to the official prescribing information, the maximum effect of Zitanid on muscle tone and spasticity is typically observed approximately 1 to 2 hours after a single dose is administered.


Q: Do I need to change my diet while I am using Zitanid?

Official information advises maintaining consistent administration relative to meals, meaning the drug should be taken in a consistent manner (either always with food or always without it). Generally, official documents state to continue a normal diet unless otherwise directed by a healthcare provider.


Q: Is it common to feel a little tired when first starting Zitanid?

Yes, somnolence (drowsiness) and dizziness are listed as very common side effects. Regulatory documents note that these effects may be more pronounced at the start of treatment and during initial dose increases.


Q: Are there different strengths of Zitanid available?

Yes, Zitanid is supplied as 2 mg and 4 mg oral tablets. Capsule formulations are also available in different strengths, as described in the official dosage forms information.


Q: How quickly do side effects from Zitanid usually start and stop?

Side effects related to the central nervous system, such as sedation and hypotension, may be more pronounced when treatment is first initiated. These effects often relate to the time the drug is active, which is typically 3 to 6 hours post-dose.


Q: What is the official research description of Zitanid's effectiveness?

Research evidence supports the use of Zitanid for the symptomatic treatment of muscle spasticity. Studies primarily monitored objective measures such as muscle tone and the frequency of muscle spasms.


Q: Is Zitanid available as a generic medicine?

Yes, a generic version of the medication containing the active ingredient tizanidine hydrochloride is approved by the FDA and is widely available.


Q: Is Zitanid considered to have a low risk of dependency?

Zitanid is not classified as a controlled substance by the DEA, reflecting a relatively lower potential for abuse compared to scheduled drugs. However, official sources note that physical dependence can develop with regular, long-term use.


Q: Are there any side effects that are considered very rare but serious with Zitanid?

Yes, serious adverse reactions reported in the very rare frequency category include hepatic failure (severe liver injury) and severe hypersensitivity reactions like skin conditions.


Q: Does Zitanid interact with common over-the-counter pain relievers like ibuprofen?

Specific pain relievers like ibuprofen are not typically listed in the official interaction documents. The known interactions focus on potent drugs that affect liver enzymes (CYP1A2 inhibitors), the central nervous system, and blood pressure.


Q: What is the typical expectation for the duration of Zitanid's effects after one use?

The clinical effect of a single dose on muscle spasticity typically dissipates between 3 to 6 hours post-dose. This short period of activity is why the medicine is often administered multiple times throughout the day.


Q: Does Zitanid need to be used at the same time every day?

Official documents indicate the total daily amount is administered up to three times per day at regular intervals of six to eight hours, as consistency in the dosing schedule is noted.


Q: Is Zitanid available in liquid form?

Official supply information lists Zitanid as an oral tablet and a capsule formulation. No liquid form is officially listed in the general supply information for the drug.


Q: Can Zitanid affect vision or cause eye-related issues?

Yes, official safety information indicates that Amblyopia (blurred vision) was reported in 3% of patients during controlled clinical studies.


Q: Are there studies examining Zitanid's use in children or teenagers?

Use in the pediatric population is not established, as official documents state that safety and efficacy have not been demonstrated in children and adolescents.


Q: Is it possible to be allergic to Zitanid's inactive ingredients?

Yes, Zitanid is contraindicated (must not be used) in patients with a known hypersensitivity to the drug or any of its components, which includes the inactive ingredients.

How should Zitanid be stored and disposed of?

How to Store and Dispose of Zitanid (Tizanidine Hydrochloride)

Official regulatory documentation defines specific requirements for the storage and handling of Zitanid oral tablets to ensure product integrity and public safety.


Required Storage Conditions

Zitanid must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F). The product must be maintained in its original container and the cap must be kept tightly closed to protect the medicine from moisture. It is strictly required that the medication is kept out of the reach of children and kept from freezing.

Official Disposal Protocol

Expired or unused Zitanid should not be discarded in household trash or poured down a drain. All disposal must be carried out according to local, regional, and national regulations for pharmaceutical waste, which often involves specific take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zitanid found in:

A-Z Index: